Application of Chromosomal Instability in Early Diagnosis of Biliary Tract Carcinoma
- Conditions
- Biliary Tract Carcinoma
- Interventions
- Diagnostic Test: The extracted DNA from bile samples will be analyzed by BileCAD to determine the level of CIN.
- Registration Number
- NCT05845554
- Lead Sponsor
- Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University
- Brief Summary
Chromosomal instability (CIN) refers to ongoing chromosome segregation errors throughout consecutive cell divisions. CIN is a hallmark of human cancer, and it is associated with poor prognosis, metastasis, and therapeutic resistance. Analyzing CIN of the DNA extracted from cast-off cells in bile samples seems a promising method for diagnosing, monitoring, and predicting the prognosis of biliary tract carcinoma patients. CIN can be assessed using experimental techniques such as bulk DNA sequencing, fluorescence in situ hybridization (FISH), or conventional karyotyping. However, these techniques are either time-consuming or non-specific. The investigators here intend to study whether a new method named Bile Ultrasensitive Chromosomal Aneuploidy Detection (BileCAD), which is based on low-coverage whole-genome sequencing, can be used to analyze CIN and microbial infection analysis thus help diagnosing and treating biliary tract carcinoma patients.
- Detailed Description
Biliary tract carcinoma account for about 3% of all digestive system tumors, with potential high metastasis and invasion ability. Their early clinical symptoms lack specificity, and they are often found in late stage with poor prognosis. CIN results from errors in chromosome segregation during mitosis, leading to structural and numerical chromosomal abnormalities. It will generate genomic heterogeneity that acts as a substrate for natural selection. Furthermore, it is proved that tumors with aneuploidies and polyploidy resulting from whole-genome doubling are related with metastasis, treatment resistance, and decreased overall survival. It is estimated that 60%-80% of human tumors exhibit chromosomal abnormalities suggestive of CIN. CIN positively correlates with tumor stage and is enriched in relapsed as well as metastatic tumor specimens. Due to the ubiquity of CIN in cancer cells, it is a potentially way to detect CIN in the cast-off cells from the bile samples for diagnosing and monitoring biliary tract carcinoma patients. BileCAD is a new method to detecting CIN in the DNA sample from patients, including extracting DNA from bile, analyzing DNA by low-coverage whole-genome sequencing, processing the data by bio-information techniques, and finally optimizing the management of biliary tract carcinoma patients.The investigators intended to conduct a prospective study by analyzing bile samples from gallbladder cancers and cholangiocarcinoma patients and control groups that without any tumor in the Bile duct and gallbladder or other organs to compare the specificity and sensitivity of BileCAD test for diagnosing biliary tract carcinoma to other modalities, such as pathological diagnosis. At the same time, the consistency of BileCAD microbial analysis results and clinical microbial culture results was compared, so as to provide more reference for clinical diagnosis.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 300
- No systemic therapy or biliary tract surgery before the trial.
- Gallstones, bile duct space, obstructive jaundice and other suspected patients with biliary tract carcinoma.
- Male or female patients aged >= 18 years.
- Participants signed informed consent form.
- Age under 18 years.
- Individuals unwilling to sign the consent form or unwilling to provide the medical record.
- Individuals unwilling to participate in this trial.
- Individuals has any active autoimmune disease or history of autoimmune disease.
- Individuals have cardiac clinical symptoms or diseases that are not well controlled.
- Individuals have uncontrolled severe cerebrovascular, pulmonary and other diseases.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Biliary tract carcinoma patients The extracted DNA from bile samples will be analyzed by BileCAD to determine the level of CIN. Biliary tract carcinoma patients will be the experimental group to determine the sensitivity of BileCAD analysis. Non-cancer participants Patients The extracted DNA from bile samples will be analyzed by BileCAD to determine the level of CIN. Non-cancer participants Patients being treated for other diseases but without any tumor will provide a negative control to provide data for determining the specificity of BileCAD analysis.
- Primary Outcome Measures
Name Time Method Specificity of bile sample analysis by BileCADanalysis 12 months Number of patients "declared negative" with the BileCAD test among the patients without cancer.
Sensitivity of bile sample analysis by BileCADanalysis 12 months Number of patients "declared positive" with the BileCAD test among the patients suffered from biliary tract carcinoma.
- Secondary Outcome Measures
Name Time Method BileCAD analyzed the sensitivity of different types and locations of malignant tumors 12 months The tumors were classified into different types and sites and the sensitivity of BileCAD to different types and sites of malignant tumors was calculated.
BileCAD microbial analysis results 12 months Consistency of BileCAD microbial analysis results with clinical microbial culture results
Trial Locations
- Locations (4)
First Affiliated Hospital of Wenzhou Medical University
🇨🇳Wenzhou, Zhejiang, China
Taizhou First People's Hospital
🇨🇳Taizhou, Zhejiang, China
Taizhou Hospital of Zhejiang Province
🇨🇳Taizhou, Zhejiang, China
Sir Run Run Shaw Hospital, School of Medicine，Zhejiang University
🇨🇳Hangzhou, Zhejiang, China